Weekly Ards Research Analysis
This week’s ARDS literature emphasizes pragmatic diagnostics, standardized endpoints, and ventilator-strategy personalization. A high-quality meta-analysis supports point-of-care lung ultrasound (especially ≥8-zone ICU protocols) as a reliable adjunct for ARDS diagnosis. An expert Delphi provides the first operational definition of ARDS resolution, enabling harmonized trial endpoints. Bayesian re-analysis of RELAx highlights heterogeneity in PEEP effects, supporting individualized PEEP strategie
Summary
This week’s ARDS literature emphasizes pragmatic diagnostics, standardized endpoints, and ventilator-strategy personalization. A high-quality meta-analysis supports point-of-care lung ultrasound (especially ≥8-zone ICU protocols) as a reliable adjunct for ARDS diagnosis. An expert Delphi provides the first operational definition of ARDS resolution, enabling harmonized trial endpoints. Bayesian re-analysis of RELAx highlights heterogeneity in PEEP effects, supporting individualized PEEP strategies in non-ARDS ICU patients.
Selected Articles
1. Lung Ultrasound for Acute Respiratory Distress Syndrome Diagnosis: A Systematic Review and Meta-analysis.
Meta-analysis of 16 studies (n=5,888) found lung ultrasound (LUS) has pooled sensitivity 0.75, specificity 0.87 and AUROC 0.91 for ARDS diagnosis. Performance improved with ≥8-zone protocols, in ICU settings, and for severe ARDS, but heterogeneity and modest sensitivity mean negative LUS should not be used alone to exclude ARDS.
Impact: Provides consolidated quantitative evidence supporting point-of-care LUS as a rapid, radiation-free diagnostic adjunct with practical guidance on scanning protocols and settings that optimize accuracy.
Clinical Implications: Incorporate LUS into ARDS diagnostic pathways (prioritize ≥8-zone protocols and trained operators), especially where CT is unavailable; interpret negative scans cautiously and use LUS as part of multimodal assessment.
Key Findings
- Pooled sensitivity 0.75 and specificity 0.87 for ARDS with AUROC 0.91.
- Higher diagnostic performance with ≥8-zone scanning protocols, ICU settings, and severe ARDS.
- Substantial heterogeneity across studies; negative LUS should not exclude ARDS.
2. Defining the Resolution of Acute Respiratory Distress Syndrome: A Delphi Consensus Study.
A 3‑round modified Delphi of 19 ARDS experts produced operational criteria for ARDS resolution: sustained PaO2/FiO2 >300 (or SpO2/FiO2 >315) for >24 hours plus normalization of respiratory support (minimal ventilatory assistance if intubated, or weaning off CPAP/NIV/HFNC/oxygen).
Impact: Fills a critical gap by operationalizing ARDS 'resolution' to harmonize trial endpoints, registries, and quality metrics—facilitates comparable recovery reporting.
Clinical Implications: Adopt these operational criteria in research and quality improvement to standardize recovery endpoints; prospective validation across ARDS etiologies is required prior to guideline adoption.
Key Findings
- Consensus definition: PaO2/FiO2 >300 (or SpO2/FiO2 >315) sustained >24 hours plus normalization of respiratory support.
- Operational, measurable elements enable reproducible endpoint application in trials/registries.
- 70% prespecified agreement threshold; 16 of 19 experts contributed to final consensus after three rounds.
3. Effect of a Lower Vs. Higher Positive End-Expiratory Pressure Strategy on Clinically Relevant Outcomes in ICU Patients Without Acute Respiratory Distress Syndrome: Bayesian Re-analysis of the REstricted Vs. Liberal Positive End-Expiratory Pressure in Patients Without Acute Respiratory Distress Syndrome (RELAx) Randomized Clinical Trial.
Bayesian re-analysis of the RELAx RCT (n=980) indicated a 75–78% probability that lower PEEP (0–5 cmH2O) yields higher ventilator-free days at day 28 compared with higher PEEP (8 cmH2O), with stronger probability of benefit in prespecified subgroups (non-cardiac arrest admissions, non-respiratory intubations). Results highlight heterogeneity of treatment effect and support individualized PEEP titration.
Impact: Reframes frequentist non-inferiority findings into probabilistic clinical guidance, showing where lower PEEP is likely beneficial and motivating subgroup-focused ventilator strategies and trials.
Clinical Implications: For invasively ventilated non-ARDS ICU patients, consider lower PEEP as a reasonable default with attention to subgroup characteristics; integrate physiologic phenotyping when titrating PEEP and pursue Bayesian-informed trials for validation.
Key Findings
- Lower PEEP had an OR 1.08 (95% CrI 0.87–1.35) for higher VFD-28 with 75–78% probability of superiority across priors.
- Probability of benefit for 28-day mortality ranged 72–89%; ventilation duration probability 11–28%.
- In prespecified subgroups (non–cardiac arrest admissions, non-respiratory intubations), probability of benefit exceeded 90%.